Abstract: This disclosure is directed, at least in part, to GPR40 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR40 agonists are gut-restricted compounds. In some embodiments, the GPR40 agonists are full agonists or partial agonists. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.

Abstract: Disclosed are a core-shell structure type wave absorbing material and a preparation method therefor. The wave absorbing material has a core-shell structure with two-dimensional transition metal-chalcogen compound nanosheets as cores and hollow carbon spheres as shells. The preparation method includes: dissolving the hollow carbon spheres in a solvent, sequentially adding a transition metal source and a chalcogen source, taking a solvothermal reaction after dissolution through stirring, and then performing posttreatment to obtain the wave absorbing material. The present invention further discloses an application of the wave absorbing material in fields of military and civilian high-frequency electromagnetic compatibility and protection. The core-shell structure type wave absorbing material of the present invention has a density of 0.3 to 1.

Abstract: The present application relates to a test strip process device. The test strip process device includes an inner cylinder, an outer cylinder, a mounting cover and a liquid supply assembly. One end of the outer cylinder is open, and the other end of the outer cylinder is closed. Both ends of the inner cylinder are open, and the inner cylinder is located in the outer cylinder. An end of the inner cylinder away from the open end of the outer cylinder is hermetically connected to the inner side wall of the outer cylinder, and a test strip chamber is formed between an outer peripheral wall of the inner cylinder and an inner peripheral wall of the outer cylinder. The mounting cover is detachably connected to an end wall of the open end of the outer cylinder, and the liquid supply assembly is provided on the mounting cover.

Abstract: This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists, super agonists, full agonists, or partial agonists.

Abstract: This disclosure is directed, at least in part, to GPR40 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR40 agonists are gut-restricted compounds. In some embodiments, the GPR40 agonists are full agonists or partial agonists. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.

Abstract: This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists or partial agonists.

Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Abstract: Provided is a speaker box and a mobile terminal. The speaker box is applied to the mobile terminal and includes a shell having a receiving space and a speaker unit received in the receiving space. The shell includes a bottom shell and a metal top plate covering the bottom shell and together defining the receiving space. The metal top plate includes a main body covering one end of the sidewall away from the bottom wall and a connector extending outwards from the main body. A positioning portion is provided in the connector. The housing extends toward the connector to form a heat stake supporting and fixing the connector. The connector is fixed to the housing after hot melting of the heat stake. A stable connection between the speaker box and the mobile terminal can be achieved and mounting is fast and firm.

Abstract: This disclosure is directed, at least in part, to GPR119 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR119 agonists are gut-restricted compounds. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.

Abstract: The invention relates to a scintillation material of rare earth orthosilicate doped with a strong electron-affinitive element and its preparation method and application thereof. The chemical formula of the scintillation material of rare earth orthosilicate doped with the strong electron-affinitive element is: RE2(1?x?y+?/2)Ce2xM(2y??)Si(1??)M?O5. In the formula, RE is rare earth ions and M is strong electron-affinitive doping elements; the value of x is 0<x?0.05, the value of y is 0<y?0.015, and the value of ? is 0???10?4; and M is selected from at least one of tungsten, lead, molybdenum, tellurium, antimony, bismuth, mercury, silver, nickel, indium, thallium, niobium, titanium, tantalum, tin, cadmium, technetium, zirconium, rhenium, and gallium Ga.

Abstract: The present invention relates to a new compound and a preparation method thereof. The general structural formula of the compound is shown in Formula I. Animal experiments show that the compound has the effect of saving the memory of animal models. It is of high safety, has no mutagenicity, can remain in blood for several hours after oral or intravenous injection, and can enter the brain. The compound can be used for preparing a medicament for treating Alzheimer's disease.

Abstract: This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists or partial agonists.

Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Abstract: The present disclosure provides systems for smart security. The system may include a smart security device, a control module, a driving module, and a mechanical structure. The control module may be configured to send a control instruction to the driving module. The driving module may be configured to drive the mechanical structure based on the control instruction, thereby performing a state switching operation of the smart security device.

Abstract: Provided is an indole compound. In particular, disclosed are a compound represented by formula (II) or an isomer or pharmaceutically acceptable salt thereof and a use of the same as an estrogen receptor antagonist in preparing a drug for treating estrogen receptor-positive breast cancer.

Abstract: This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists or partial agonists.

Abstract: Disclosed are protective coating compositions having enhanced gloss retention properties formed by steps comprising: (i) providing one or more fluorocopolymers by copolymerization of (1) one or more hydrofluoroolefin monomer(s) selected from the group consisting of hydrofluoroethylenes, hydrofluoropropenes, hydrofluorobutenes, hydrofluoropentenes and combinations of these, (2) one or more vinyl ester monomer(s), and (3) one or more vinyl ether monomer(s), wherein at least a portion of said vinyl ether monomer is a hydroxyl group-containing vinyl ether monomer, wherein the copolymer preferably has a number average molecular weight of greater than about 10,000; (ii) providing a VOC containing carrier for said one or more fluorocopolymers; and (iii) providing a stabilizing agent comprising: a) a radical scavenger and b) an absorber of UV light; and (iv) combining said one or more fluorocopolymers with said carrier and said stabilizing agent to produce a polymeric coating composition.